Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Eur Respir J. 2013 Jul;42(1):230-8. doi: 10.1183/09031936.00038613. Epub 2013 May 16.
Pulmonary fibrosis is the ultimate outcome of various interstitial lung diseases, many of which have a dismal prognosis. Pulmonary fibrosis, therefore, represents a critical unmet medical need. Progress in research over the past 30 years has been encouraging. This work, which has been funded by governments, charitable trusts, industries and patient groups, has resulted in clinical trials testing novel drugs, giving hope to patients. In late September 2012, representatives from academia, industry and funding agencies met at the 17th International Colloquium on Airway and Lung Fibrosis to discuss state-of-the-art knowledge of pulmonary fibrosis. This manuscript summarises the outcomes of the meeting, highlighting the most relevant results and discoveries. It also attempts to provide a roadmap for future studies. It is hoped that such a roadmap may help interested parties to generate new research, which will be vital to continued progress. We are encouraged by the commitment expressed by all participants at this meeting and the shared vision of promoting future progress through international collaboration, the pooling of valuable resources, and the involvement of a new generation of physicians and scientists.
肺纤维化是各种间质性肺疾病的最终结果，其中许多疾病预后不良。因此，肺纤维化代表了一个亟待满足的重大医疗需求。过去 30 年来的研究进展令人鼓舞。这些工作得到了政府、慈善信托、行业和患者团体的资助，开展了测试新型药物的临床试验，为患者带来了希望。2012 年 9 月下旬，学术界、工业界和资助机构的代表在第 17 届气道和肺纤维化国际学术研讨会上齐聚一堂，讨论肺纤维化的最新知识。本文总结了会议的成果，突出了最相关的结果和发现。它还试图为未来的研究提供路线图。希望这样的路线图可以帮助有兴趣的各方开展新的研究，这对于持续进展至关重要。我们受到了与会者的承诺和通过国际合作、宝贵资源的共享以及新一代医生和科学家的参与来推动未来进展的共同愿景的鼓舞。
